1 / 18

What are SNPs ? Single Nucleotide Polymorphism

“ From Genetics t o Pharmacogenomics ”. What are SNPs ? Single Nucleotide Polymorphism. SNP Genetics. What are SNPs ?. ACGTTTG G ATAC. ACGTTTG T ATAC. TGCAAAC C TATG. TGCAAAC A TATG. Single nucleotide polymorphisms consist of a single change in the DNA code

hung
Download Presentation

What are SNPs ? Single Nucleotide Polymorphism

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. “FromGeneticstoPharmacogenomics ” What are SNPs ? Single Nucleotide Polymorphism SNP Genetics

  2. What are SNPs ? ACGTTTGGATAC ACGTTTGTATAC TGCAAACCTATG TGCAAACATATG • Single nucleotide polymorphisms consist of a single • change in the DNA code • SNPs occur with various allele frequencies. Those in • the 20-40% range are useful for genetic mapping. • Those at frequencies between 1% and 20% may be • used with candidate gene approaches. Usually bi-allelic. • Changes at 〈1% are called variants

  3. What are the effects of SNPs ?

  4. How many SNPs are there ? • It is estimated that the human genome contains between • 3 million and 6 million SNPs spaced irregularly at • intervals of 500 to 1,000 bases. • The SNP Consortium estimates that as many as 300,000 • SNPs may be needed to fuel studies. • 100.000 or more SNPs may be required for complex • disease gene discovery

  5. Applications • SNP Discovery • SNP Validation • - Fine Mapping • SNP Screening • - Testing

  6. SNP Discovery • SNP Discovery refers to the initial identification of new • SNPs. • The established method is electrophoresis(DNA sequencing) • with subsequent data analysis. Some indirect Discovery • techniques (e.g., dHPLC, SSCP) only indicate that a SNP • (or other mutation) exists. • DNA sequencing of multiple individuals is used to determine • the point and type of polymorphism. • Low throughput, based on established DNA sequencing • analyses or collected data (also based on electrophoretic data)

  7. SNP Validation • SNP Validation refers to genetic validation, the process • of ensuring that the SNP is not due to sequencing error • and that it is not extremely rear. This should not be • confused with assay, target or regulatory validation. • Confirmation of SNPs found in Discovery • Larger numbers of individual samples to get statistical • data on occurrence in the population

  8. SNP Screening • SNP Screening refers to researchers running thousands of • genotypes (may SNPs or many individuals or both) • Thousands to hundreds of thousands of samples per day • Two different screening strategies • - Many SNPs in a few individuals • - A few SNPs in many individuals • Different strategies will require different tools • Important in determining markers for complex genetic states

  9. SNP analysis costs are dependent on volume • Costs per assay are dependent upon the number of SNPs • being analyzed and the number of individuals. • Running cost • - one SNP in 100 individuals∼range $5∼$8/assay • - one SNP in 1,000 individuals∼range $3∼$5/assay. • - 1000 SNPs in 1000 individuals∼range $1.5~$3.00/assay. • - All these costs include the cost of the PCR step. • Future high through-put costs/assay will be driven toward • pennies per SNP.

  10. What is a DNA Array ? • A collection of nucleic acid probes which are • attached to a surface in a predetermined grid • This grid is exposed to targets from a biological • sample and the complementary pairs are detected • ("hybridization") • The complementary pairs are scored by software

  11. What Good are DNA Arrays ? • Arrays • - nucleotide changes anywhere in a genome • - identity of and amount of unique mRNAs • - re-sequencing • Ideal for Screening large# SNPs: • Present formats not really a high throughput format • but by their massive parallelism they enable certain • types of analyses, e.g. global expression profiling or • genome wide SNP screening

  12. DNA Arrays Are Valuable • Arrays allow massively parallel analysis for certain • applications this parallelism is enabling...i.e., global • expression profiling • For certain applications there may be labor savings..i.e., • comparative sequencing • But...the present formats are not yet high throughput • technology Platform Extensions for SNP Screening in • Pharmaceuticals

  13. Researcher determinants • Infrastructure: • - Lab. Instrument, labor & expertise • Investment: • - Start-up cost & running cost • Jobs: • - How big sample size ? • - How many SNPs ? • Best Choice • - Out-sourcing ?

  14. Technology Platform Extension for SNP Screening High Array # of SNPs Mass Spec. RFLP TaqMan SBE Low Low # of Individuals High

  15. Addendum

  16. TSC I : The SNP Consortium • Pharmaceutical Partners: • AstraZeneca, Bayer, Bristol-Myers Squibb Co., • GlaxoWellcome PLC, Hoffmann-LaRoche, Hoechst • Marion Roussei, (now merged with RPR to form • Aventis), Merck, Pfizer lnc, Searle, SmithKline • Beecham PLC. • Academic Partners: • The Whitehead lnstitute at MIT, Wellcome Trust at • the Sanger Center,Stanford

  17. TSC II : The SNP Consortium • At least $45 million ($3 million per pharmaceutical • company, $14 million form Wellcome Trust) • Reduction from %150 million in large part to the • efforts of Celera and NHGRI to sequence entire • genome.

  18. What is happening now ? • Japanese SNP Project: • $ 5 Million over next two years to map 100K to 150K • SNPs. Probably concentrated at one site (U. Tokyo's • Human Genome Center) • Funded by Science & Technology Agency, Ministry of • Health & Welfare and private sector.

More Related